ABSTRACT:
The purpose of the present research work was to develop a robust and physicochemically stable pMDI formulation for pulmonary delivery of an Glucocorticoide, drug-Beclomethasone. The pMDI was quickly developed, providing a reliable dose in a robust, convenient and multi-dose preparation. Fortunately, at that time, metering valves capable of developing at least 100 precise spray doses had just become available. Sprays from pMDIs are self-propelled, the pressure of propellants inside the canister being used to force the spray out of the pressure of propellants inside the canister being used to force the spray out of the device via a narrow nozzle in the plastic actuator.Beclometasone dipropionate is a pro-drug with weak glucocorticoid receptor binding affinity. It is extensively hydrolysed via esterase enzymes to the active metabolite beclometasone-17 monopropionate (B-17-MP), which has potent topical anti-inflammatory activity. Formulation contains Anhydrous Beclometasone Dipropionate (Micronised) , Ethanol , Oleic Acid , HFA 134a(1,1,1,2 Tetrafluoro Ethane), HFA 227ea (1,1,1,2,3,3,3- Heptafluoro Propane) , Propylene Glycol , PEG 300, PEG 1000, Povidone K-25. formulation was evaluated for fine particle dose, mass median aerodynamic diameter, uniformity of dose, leak test, water content, net content, no of doses. Hence it was concluded that pressurised based MDI formulation in an attempt to develop pulmonary administrable product of Beclomethasone was found to be stable and robust with desired attributes of packaging requirements.